The new chief executive of Germany’s Stada, who took over after his predecessor Harmut Retzlaff left for health reasons, has stripped Retzlaff’s son Steffen of some responsibilities and has fired the former CEO’s external advisors, taking a firmer grip of the maker of generic drugs and consumer care products.
Stada earlier this month said its long-time chief executive Harmut Retzlaff would temporarily leave office for health reasons and that fellow executive board member Matthias Wiedenfels would take over as CEO.
Steffen Retzlaff will no longer be in charge of Stada subsidiaries Hemopharm GmbH and Stadavita GmbH and will focus on his responsibility for the regions Asia and Pacific, Middle East and North Africa, Wiedenfels told staff in a letter dated June 20, which was obtained by Reuters.
A company spokesman confirmed the contents of the letter.
External advisors which have been acting as “Senior Advisors to the CEO” have been relieved of their duties, Wiedenfels told staff in the letter.
By Alexander Huebner
Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]
Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]
Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]